JP2005508318A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508318A5
JP2005508318A5 JP2003528493A JP2003528493A JP2005508318A5 JP 2005508318 A5 JP2005508318 A5 JP 2005508318A5 JP 2003528493 A JP2003528493 A JP 2003528493A JP 2003528493 A JP2003528493 A JP 2003528493A JP 2005508318 A5 JP2005508318 A5 JP 2005508318A5
Authority
JP
Japan
Prior art keywords
group
alkyl
aryl
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003528493A
Other languages
English (en)
Japanese (ja)
Other versions
JP4269052B2 (ja
JP2005508318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/029232 external-priority patent/WO2003024395A2/en
Publication of JP2005508318A publication Critical patent/JP2005508318A/ja
Publication of JP2005508318A5 publication Critical patent/JP2005508318A5/ja
Application granted granted Critical
Publication of JP4269052B2 publication Critical patent/JP4269052B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003528493A 2001-09-14 2002-09-13 連結ビアリール化合物 Expired - Fee Related JP4269052B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32255601P 2001-09-14 2001-09-14
US33543401P 2001-11-30 2001-11-30
US37862702P 2002-05-07 2002-05-07
US38683302P 2002-06-06 2002-06-06
PCT/US2002/029232 WO2003024395A2 (en) 2001-09-14 2002-09-13 Linked biaryl compounds

Publications (3)

Publication Number Publication Date
JP2005508318A JP2005508318A (ja) 2005-03-31
JP2005508318A5 true JP2005508318A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4269052B2 JP4269052B2 (ja) 2009-05-27

Family

ID=27502245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528493A Expired - Fee Related JP4269052B2 (ja) 2001-09-14 2002-09-13 連結ビアリール化合物

Country Status (13)

Country Link
US (2) US6869975B2 (cg-RX-API-DMAC7.html)
EP (1) EP1435946B8 (cg-RX-API-DMAC7.html)
JP (1) JP4269052B2 (cg-RX-API-DMAC7.html)
KR (1) KR20040063897A (cg-RX-API-DMAC7.html)
CN (1) CN1585638A (cg-RX-API-DMAC7.html)
AU (1) AU2002336532C1 (cg-RX-API-DMAC7.html)
BR (1) BR0212512A (cg-RX-API-DMAC7.html)
CA (1) CA2460313C (cg-RX-API-DMAC7.html)
ES (1) ES2443642T3 (cg-RX-API-DMAC7.html)
IL (1) IL160845A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04002330A (cg-RX-API-DMAC7.html)
NZ (1) NZ531917A (cg-RX-API-DMAC7.html)
WO (1) WO2003024395A2 (cg-RX-API-DMAC7.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP4269052B2 (ja) 2001-09-14 2009-05-27 アムジエン・インコーポレーテツド 連結ビアリール化合物
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JPWO2005012221A1 (ja) * 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
JP2007536341A (ja) * 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
US8053598B2 (en) * 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
DE602005024384D1 (de) * 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
DE602005020313D1 (de) * 2004-08-12 2010-05-12 Amgen Inc Bisaryl-sulfonamide
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
US20060135540A1 (en) * 2004-11-30 2006-06-22 Jack Lin PPAR active compounds
AU2005311925A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR PPAR active compounds
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
FR2880886B1 (fr) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102005020230A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
DE102005020229A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
US20090118337A1 (en) * 2005-06-03 2009-05-07 Davis Pamela B Methods and compositions for treating inflammation
ES2449618T3 (es) 2005-06-30 2014-03-20 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de PPAR-delta
EP1911738A4 (en) * 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
NZ567162A (en) * 2005-09-07 2011-06-30 Plexxikon Inc 1, 3-disubstituted indole derivatives for use as PPAR modulators
JP2009509932A (ja) * 2005-09-07 2009-03-12 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
WO2007030567A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
ES2614090T3 (es) 2005-12-29 2017-05-29 Celtaxsys, Inc. Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
CA2708391A1 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
JP5607025B2 (ja) 2008-04-21 2014-10-15 シグナム バイオサイエンシーズ， インコーポレイテッド 化合物、組成物およびそれらを作製する方法
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
KR20120115989A (ko) * 2010-01-06 2012-10-19 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
BR122021002201A8 (pt) 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
EP2968359B1 (en) 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
EP2970309A4 (en) 2013-03-14 2016-11-09 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
RU2690489C2 (ru) 2013-03-14 2019-06-04 Селтакссис, Инк. Ингибиторы лейкотриен а4-гидролазы
US9487493B2 (en) 2013-09-09 2016-11-08 Vtv Therapeutics Llc Use of a PPAR-delta agonist for treating muscle atrophy
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
CN113912547B (zh) * 2020-07-10 2024-04-30 成都凡诺西生物医药科技有限公司 取代苯丙咪唑类衍生物及其应用
IL300000A (en) 2020-07-22 2023-03-01 Reneo Pharmaceuticals Inc PPAR agonist - crystalline delta
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038934A (en) * 1959-03-17 1962-06-12 Smith Kline French Lab Iodinated 4-(4'-alkoxyphenoxy)phenylpropionic acids
US4443536A (en) * 1981-08-25 1984-04-17 Eastman Kodak Company Nondiffusible photographic couplers and photographic elements and processes employing same
US4466902A (en) * 1982-01-31 1984-08-21 Ipposha Oil Industries, Co., Ltd. Rust inhibitor
DE68923591T2 (de) * 1988-09-14 1996-03-28 Eastman Kodak Co Photographisches Aufzeichnungsmaterial mit Magenta-Kuppler und einem Chalcogenazoliumsalz.
JPH10502256A (ja) 1994-07-01 1998-03-03 ザ ソールク インスチチュート フォア バイオロジカル スタディズ 哺乳動物のペルオキシソーム増殖物質活性化受容体およびその使用
CA2245529A1 (en) 1996-02-02 1997-08-07 Soumya P. Sahoo Antidiabetic agents
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
ES2217392T3 (es) 1996-02-02 2004-11-01 MERCK & CO., INC. Agentes antidiabeticos.
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
ES2194179T3 (es) 1996-02-02 2003-11-16 Merck & Co Inc Derivados heterociclicos como agentes antidiabeticos y antiobesidad.
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
WO1998043943A1 (fr) * 1997-03-27 1998-10-08 Taisho Pharmaceutical Co., Ltd. Derives de 2-phenoxyaniline
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6346639B1 (en) 1997-12-23 2002-02-12 The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization Boronic compounds
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6200995B1 (en) 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
CN1245380C (zh) * 1998-07-24 2006-03-15 帝人株式会社 邻氨基苯甲酸衍生物
CA2374263A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylether derivatives
JP2003502369A (ja) 1999-06-18 2003-01-21 メルク エンド カムパニー インコーポレーテッド アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
WO2001000579A1 (en) 1999-06-30 2001-01-04 Tularik Inc. COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY
CA2382966A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
ES2215719T3 (es) 1999-09-08 2004-10-16 Glaxo Group Limited Antagonista ppar oxazol.
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
HUP0301482A3 (en) 2000-06-28 2005-12-28 Japan Tobacco Inc Quinolinnyl and benzothiazolyl ppar-gamma modulators pharmaceutical compositions containing them and their use
DE60128475T2 (de) 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
JP4790969B2 (ja) 2000-08-11 2011-10-12 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
GB0024362D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1357914A2 (en) 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
ES2328795T3 (es) * 2001-02-14 2009-11-18 Karo Bio Ab Moduladores del receptor glucocorticoide.
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
EP1371650A4 (en) 2001-03-23 2005-05-04 Nippon Chemiphar Co ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS
WO2003018515A2 (en) * 2001-08-24 2003-03-06 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
JP4269052B2 (ja) 2001-09-14 2009-05-27 アムジエン・インコーポレーテツド 連結ビアリール化合物
DE60223699T2 (de) * 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
US7230031B2 (en) * 2002-01-30 2007-06-12 Kissei Pharmaceutical Co., Ltd. Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Similar Documents

Publication Publication Date Title
JP2005508318A5 (cg-RX-API-DMAC7.html)
CA2460313A1 (en) Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels
CN101595105B (zh) 作为scd抑制剂的2-取代的5元杂环化合物
TWI339121B (en) 1-piperazine- and 1-homopiperazine-carboxylate derivatives, preparation and therapeutic application thereof
CN102030700B (zh) 苯甲酰胺基羧酸类化合物及其制法和药物用途
US5606073A (en) Diazole-propenoic acid compounds
SG192439A1 (en) Organic compounds
AU2006212761A1 (en) Combination therapy
TW200523250A (en) Compounds for inflammation and immune-related uses
JP2010526807A5 (cg-RX-API-DMAC7.html)
JP2007500720A5 (cg-RX-API-DMAC7.html)
JP2009513703A5 (cg-RX-API-DMAC7.html)
JP2004529161A5 (cg-RX-API-DMAC7.html)
CN109641843A (zh) 作为apj激动剂的4-羟基-3-磺酰基吡啶-2(1h)-酮
CN111285829A (zh) 一类PPARγ/δ双重激动剂、其制备方法及其作为药物的用途
WO2010069124A1 (zh) 酰胺基噻唑衍生物及其制备方法和用途
CN109111426A (zh) 一类稠合双环杂芳基或芳基化合物，及其用途
JPWO2015199234A1 (ja) ハロゲン置換へテロ環化合物の塩
AU2015336458A1 (en) KCNQ2-5 channel activator
CN101068784A (zh) 间烟碱化合物的羟基苯甲酸盐
CN108727295A (zh) 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
JP2010531322A (ja) アントラニルアミドピリジンウレア及びベンズアミド誘導体の相乗組合せ
JPWO2001036402A1 (ja) 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JP2009506127A (ja) 糖尿病の処置に有用なアニリノピラゾール誘導体
CN106117182B (zh) 喹唑啉-n-苯乙基四氢异喹啉类化合物及其制备方法和应用